PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

BACKGROUND: After liver resection (LR), patients with hepatocellular cancer (HCC) are at high risk of recurrence. There are no approved anti-cancer therapies known to affect such risk, highlighting the acute need for novel systemic therapies to control the probability of disease relapse. Immunothera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Pinato, David J., Cortellini, Alessio, Sukumaran, Ajithkumar, Cole, Tom, Pai, Madhava, Habib, Nagy, Spalding, Duncan, Sodergren, Mikael H., Martinez, Maria, Dhillon, Tony, Tait, Paul, Thomas, Robert, Ward, Caroline, Kocher, Hemant, Yip, Vincent, Slater, Sarah, Sharma, Rohini
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7988931/
https://ncbi.nlm.nih.gov/pubmed/33757459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08033-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados